Athira Pharma Awarded $15 Million Grant from National Institute on Aging to Support ACT-AD Clinical Trial in Alzheimer's DiseaseGlobeNewsWire • 12/08/20
Athira Pharma Announces Initiation of Patient Dosing for ACT-AD Clinical Trial of ATH-1017, Small Molecule HGF/MET Activator, for Treatment of Mild-to-Moderate Alzheimer's DiseaseGlobeNewsWire • 12/01/20
Athira Pharma Reports Third Quarter 2020 Financial Results and Provides Business HighlightsGlobeNewsWire • 11/12/20
Athira Pharma to Host Educational Webinar on the Predictive Nature of P300 to Determine Clinical Benefit of Alzheimer's Disease TreatmentsGlobeNewsWire • 10/21/20
Athira Pharma Announces Initiation of Patient Dosing for the LIFT-AD Study, a Phase 2/3 Clinical Trial to Evaluate ATH-1017 for Treatment of Mild-to-Moderate Alzheimer's DiseaseGlobeNewsWire • 10/01/20
Athira Pharma raises $204M in IPO, reaching ‘big milestone’ in fight against Alzheimer’s and other diseasesGeekWire • 09/18/20
Athira Pharma's stock jumps at its open, with the first trade 17% above the IPO priceMarket Watch • 09/18/20
Athira Pharma prices IPO at $17/share, will raise $204M in third Washington state IPO of 2020GeekWire • 09/18/20